Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Talphera ( (TLPH) ) is now available.
On October 14, 2025, Talphera, Inc. appointed Joseph Todisco as a Class III member of its board of directors and member of the compensation committee, with his term expiring at the 2026 annual meeting of stockholders. Mr. Todisco, currently the CEO of CorMedix Inc., has a rich background in the pharmaceutical industry, having held senior roles at Amneal Pharmaceuticals and co-founding Gemini Laboratories. His appointment is linked to a securities purchase agreement with CorMedix, which grants CorMedix the right to designate a board member as long as they hold at least 25% of their purchased shares. Additionally, CorMedix has a Right of First Negotiation for acquiring Talphera, contingent on the results of the NEPHRO CRRT clinical study for Talphera’s product candidate Niyad.
The most recent analyst rating on (TLPH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Talphera stock, see the TLPH Stock Forecast page.
Spark’s Take on TLPH Stock
According to Spark, TipRanks’ AI Analyst, TLPH is a Neutral.
Talphera faces significant financial hurdles with negative income and cash flows, impacting its overall score. While technical indicators are mixed, the stock is underperforming key moving averages. Valuation remains a challenge with a negative P/E ratio. The earnings call provided some optimism with regulatory approvals and financing, but operational challenges persist. The combination of these factors results in a low overall score.
To see Spark’s full report on TLPH stock, click here.
More about Talphera
Average Trading Volume: 2,467,925
Technical Sentiment Signal: Buy
Current Market Cap: $50.6M
Find detailed analytics on TLPH stock on TipRanks’ Stock Analysis page.